| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
2-Chloro-N6-furfuryladenine is a kinetin riboside derivative. Kinetin and its derivatives are cytokinins, plant hormones that regulate cell division and differentiation. In mammalian systems, kinetin derivatives have been studied for their antioxidant and anti-aging properties. However, the specific molecular target of this compound is not well-defined. As a fragment molecule, it serves as a building block for drug discovery rather than having a defined biological target.
|
|---|---|
| ln Vitro |
2-Chloro-N6-furfuryladenine is not typically evaluated for in vitro biological activity as a drug; it is a fragment molecule and synthetic intermediate used in drug discovery. As a kinetin riboside analogue, it may have cytokinin-like activity in plant systems or antioxidant properties in mammalian cells. However, specific IC50 values and detailed in vitro activity data are not extensively reported in the available literature.
|
| ln Vivo |
2-Chloro-N6-furfuryladenine is not evaluated for in vivo biological activity as a drug; it is a fragment molecule and research chemical. As a kinetin derivative, it may have potential effects on cell proliferation and differentiation, but specific in vivo efficacy data are not extensively reported. The compound is primarily used as a building block for the synthesis of more complex molecules.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for 2-Chloro-N6-furfuryladenine as a drug target. As a fragment molecule, it is typically characterized by its chemical properties rather than biological activity. The compound may be used in fragment-based drug discovery screens, where it is tested for binding to target proteins using techniques such as surface plasmon resonance, NMR, or X-ray crystallography. However, specific protocols are not extensively reported.
|
| Cell Assay |
There are no specific in vitro cellular assays for 2-Chloro-N6-furfuryladenine as a pharmacologically active compound. As a fragment molecule, it may be used in cell-based assays to assess its effects on cell proliferation or signaling pathways, but specific protocols are not extensively reported. The compound is primarily used in medicinal chemistry for the synthesis of novel drug candidates.
|
| Animal Protocol |
There are no specific in vivo animal studies for 2-Chloro-N6-furfuryladenine as a pharmacologically active compound. As a fragment molecule and research chemical, it is not typically administered to animals for efficacy studies. The compound is used in the synthesis of more complex molecules that may subsequently be tested in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Chloro-N6-furfuryladenine are not reported, as it is a fragment molecule rather than a drug. The compound has a molecular weight of 249.66 and is expected to have moderate lipophilicity. Specific PK parameters such as oral bioavailability, half-life, and tissue distribution are not applicable or reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2-Chloro-N6-furfuryladenine is not extensively reported. As a fragment molecule and research chemical, it is not intended for human therapeutic use. Standard safety data are not available. The compound should be handled with care in a laboratory setting. No specific genotoxicity or carcinogenicity data are reported.
|
| Additional Infomation |
2-Chloro-N6-furfuryladenine (CAS 101862-47-9) is a kinetin riboside analogue and fragment molecule used as a building block in drug discovery. It has a molecular formula of C10H8ClN5O and a molecular weight of 249.66. The compound provides a structural basis for the design and screening of novel drug candidates. It is available for research purposes only and is not intended for therapeutic use.
|
| Molecular Formula |
C10H8CLN5O
|
|---|---|
| Molecular Weight |
249.656419754028
|
| Exact Mass |
249.041
|
| CAS # |
101862-47-9
|
| PubChem CID |
5037694
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
499.4±45.0 °C at 760 mmHg
|
| Flash Point |
255.8±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.756
|
| LogP |
2.07
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
269
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1N=C2C(=C(N=1)NCC1=CC=CO1)NC=N2
|
| InChi Key |
QGUOPVCOXHVPJX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8ClN5O/c11-10-15-8(7-9(16-10)14-5-13-7)12-4-6-2-1-3-17-6/h1-3,5H,4H2,(H2,12,13,14,15,16)
|
| Chemical Name |
2-chloro-N-(furan-2-ylmethyl)-7H-purin-6-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0054 mL | 20.0272 mL | 40.0545 mL | |
| 5 mM | 0.8011 mL | 4.0054 mL | 8.0109 mL | |
| 10 mM | 0.4005 mL | 2.0027 mL | 4.0054 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
